Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: QYResearch | PRODUCT CODE: 1866638

Cover Image

PUBLISHER: QYResearch | PRODUCT CODE: 1866638

Mesenchymal Stem Cells - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

PUBLISHED:
PAGES: 128 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 3950
PDF (Multi User License)
USD 5925
PDF (Enterprise User License)
USD 7900

Add to Cart

The global market for Mesenchymal Stem Cells was estimated to be worth US$ 1245 million in 2024 and is forecast to a readjusted size of US$ 2542 million by 2031 with a CAGR of 10.6% during the forecast period 2025-2031.

Mesenchymal Stem Cells (MSCs) are multipotent stem cells derived from various tissues such as bone marrow, umbilical cord, adipose tissue, and placenta. They possess strong self-renewal and multilineage differentiation capabilities, enabling them to differentiate into osteoblasts, chondrocytes, adipocytes, and other mesenchymal-origin cells. MSCs are characterized by low immunogenicity, immunomodulatory effects, and robust cytokine secretion, making them a key focus in regenerative medicine, immune therapy, and anti-inflammatory treatment. With advancements in cell culture techniques, serum-free media, and GMP-compliant manufacturing, MSCs are transitioning from preclinical research to clinical applications, finding broad use in orthopedic disorders, cardiovascular diseases, autoimmune conditions, oncology, and tissue engineering. The MSC industry spans upstream cell sourcing, large-scale expansion, cryopreservation, logistics, and therapeutic product development, positioning MSCs as a cornerstone of the global cell and gene therapy (CGT) market and a critical driver of precision medicine, drawing strong attention from investors and regulatory authorities worldwide.

The mesenchymal stem cell (MSC) industry is entering a phase of accelerated growth, driven by the global boom in cell and gene therapy R&D, rising healthcare needs of aging populations, and supportive regenerative medicine policies. According to public annual reports, the number of ongoing MSC clinical trials continues to grow, with over 300 trials registered in the U.S. and China in 2024 alone, covering neurological, metabolic, and autoimmune disorders. Governments are investing heavily in innovation, supporting GMP-compliant manufacturing facilities and quality standardization, reducing technical barriers. Frequent collaborations between multinational pharmaceutical companies and regional CDMOs are facilitating industrial-scale production and rapid market penetration. With increasing investments from Asia and the Middle East, MSCs are poised to become a strategic focus in global precision and personalized medicine development.

Despite rapid growth, the MSC industry faces challenges such as complex cell sourcing, difficulties in large-scale manufacturing, inconsistent clinical protocols, and varying regulatory requirements across regions. Many companies lack mature experience in process optimization and batch consistency, resulting in high costs and extended commercialization timelines. Intellectual property barriers, cross-border clinical certifications, and global regulatory complexities further increase entry thresholds, particularly for small and mid-sized players. Market uncertainties, including fluctuations in capital markets and healthcare reimbursement policies, also pose risks. Balancing strict quality standards, cost efficiency, and accessible pricing will be critical for shaping the competitive landscape.

Demand is rapidly shifting from basic research to commercial clinical applications. The growth of immunotherapy, tissue engineering, and personalized medicine is expanding MSC use cases, including cardiovascular repair, cartilage regeneration, autoimmune disease management, anti-aging therapies, and medical aesthetics. Emerging integration with mRNA technology and gene editing is creating vast opportunities for premium, customized MSC products. Companies and research institutions are accelerating automation and digital process control to enhance product consistency and reduce costs. The convergence of aging demographics, chronic disease prevalence, and supportive policy frameworks positions MSCs as a central growth engine in the global cell therapy market over the next five years.

This report aims to provide a comprehensive presentation of the global market for Mesenchymal Stem Cells, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Mesenchymal Stem Cells by region & country, by Type, and by Application.

The Mesenchymal Stem Cells market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mesenchymal Stem Cells.

Market Segmentation

By Company

  • CellResearch
  • StemCord
  • Cytopeutics
  • CryoCord
  • Cell Malaysia
  • Bangkok Stem Cell
  • Vinmec Stem Cell Institute
  • ProSTEM
  • Cryoviva
  • StemCells21
  • Lonza
  • Thermo Fisher Scientific
  • PromoCell
  • Stemcell Technologies
  • Bio-Techne
  • ATCC
  • Merck

Segment by Type

  • Umbilical Cord Derived MSC
  • Bone Marrow Derived MSC
  • Placenta Derived MSC
  • Other

Segment by Application

  • Research
  • Disease Treatment
  • Beauty and Anti-aging
  • Storage

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Mesenchymal Stem Cells company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Mesenchymal Stem Cells in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Mesenchymal Stem Cells in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Mesenchymal Stem Cells Product Introduction
  • 1.2 Global Mesenchymal Stem Cells Market Size Forecast (2020-2031)
  • 1.3 Mesenchymal Stem Cells Market Trends & Drivers
    • 1.3.1 Mesenchymal Stem Cells Industry Trends
    • 1.3.2 Mesenchymal Stem Cells Market Drivers & Opportunity
    • 1.3.3 Mesenchymal Stem Cells Market Challenges
    • 1.3.4 Mesenchymal Stem Cells Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Mesenchymal Stem Cells Players Revenue Ranking (2024)
  • 2.2 Global Mesenchymal Stem Cells Revenue by Company (2020-2025)
  • 2.3 Key Companies Mesenchymal Stem Cells Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Mesenchymal Stem Cells Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Mesenchymal Stem Cells
  • 2.6 Mesenchymal Stem Cells Market Competitive Analysis
    • 2.6.1 Mesenchymal Stem Cells Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Mesenchymal Stem Cells Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mesenchymal Stem Cells as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Umbilical Cord Derived MSC
    • 3.1.2 Bone Marrow Derived MSC
    • 3.1.3 Placenta Derived MSC
    • 3.1.4 Other
  • 3.2 Global Mesenchymal Stem Cells Sales Value by Type
    • 3.2.1 Global Mesenchymal Stem Cells Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Mesenchymal Stem Cells Sales Value, by Type (2020-2031)
    • 3.2.3 Global Mesenchymal Stem Cells Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Research
    • 4.1.2 Disease Treatment
    • 4.1.3 Beauty and Anti-aging
    • 4.1.4 Storage
  • 4.2 Global Mesenchymal Stem Cells Sales Value by Application
    • 4.2.1 Global Mesenchymal Stem Cells Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Mesenchymal Stem Cells Sales Value, by Application (2020-2031)
    • 4.2.3 Global Mesenchymal Stem Cells Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Mesenchymal Stem Cells Sales Value by Region
    • 5.1.1 Global Mesenchymal Stem Cells Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Mesenchymal Stem Cells Sales Value by Region (2020-2025)
    • 5.1.3 Global Mesenchymal Stem Cells Sales Value by Region (2026-2031)
    • 5.1.4 Global Mesenchymal Stem Cells Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Mesenchymal Stem Cells Sales Value, 2020-2031
    • 5.2.2 North America Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Mesenchymal Stem Cells Sales Value, 2020-2031
    • 5.3.2 Europe Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Mesenchymal Stem Cells Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Mesenchymal Stem Cells Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Mesenchymal Stem Cells Sales Value, 2020-2031
    • 5.5.2 South America Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Mesenchymal Stem Cells Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Mesenchymal Stem Cells Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Mesenchymal Stem Cells Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.3.2 United States Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.4.2 Europe Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.5.2 China Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.6.2 Japan Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.7.2 South Korea Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.9.2 India Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 CellResearch
    • 7.1.1 CellResearch Profile
    • 7.1.2 CellResearch Main Business
    • 7.1.3 CellResearch Mesenchymal Stem Cells Products, Services and Solutions
    • 7.1.4 CellResearch Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.1.5 CellResearch Recent Developments
  • 7.2 StemCord
    • 7.2.1 StemCord Profile
    • 7.2.2 StemCord Main Business
    • 7.2.3 StemCord Mesenchymal Stem Cells Products, Services and Solutions
    • 7.2.4 StemCord Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.2.5 StemCord Recent Developments
  • 7.3 Cytopeutics
    • 7.3.1 Cytopeutics Profile
    • 7.3.2 Cytopeutics Main Business
    • 7.3.3 Cytopeutics Mesenchymal Stem Cells Products, Services and Solutions
    • 7.3.4 Cytopeutics Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Cytopeutics Recent Developments
  • 7.4 CryoCord
    • 7.4.1 CryoCord Profile
    • 7.4.2 CryoCord Main Business
    • 7.4.3 CryoCord Mesenchymal Stem Cells Products, Services and Solutions
    • 7.4.4 CryoCord Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.4.5 CryoCord Recent Developments
  • 7.5 Cell Malaysia
    • 7.5.1 Cell Malaysia Profile
    • 7.5.2 Cell Malaysia Main Business
    • 7.5.3 Cell Malaysia Mesenchymal Stem Cells Products, Services and Solutions
    • 7.5.4 Cell Malaysia Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Cell Malaysia Recent Developments
  • 7.6 Bangkok Stem Cell
    • 7.6.1 Bangkok Stem Cell Profile
    • 7.6.2 Bangkok Stem Cell Main Business
    • 7.6.3 Bangkok Stem Cell Mesenchymal Stem Cells Products, Services and Solutions
    • 7.6.4 Bangkok Stem Cell Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Bangkok Stem Cell Recent Developments
  • 7.7 Vinmec Stem Cell Institute
    • 7.7.1 Vinmec Stem Cell Institute Profile
    • 7.7.2 Vinmec Stem Cell Institute Main Business
    • 7.7.3 Vinmec Stem Cell Institute Mesenchymal Stem Cells Products, Services and Solutions
    • 7.7.4 Vinmec Stem Cell Institute Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Vinmec Stem Cell Institute Recent Developments
  • 7.8 ProSTEM
    • 7.8.1 ProSTEM Profile
    • 7.8.2 ProSTEM Main Business
    • 7.8.3 ProSTEM Mesenchymal Stem Cells Products, Services and Solutions
    • 7.8.4 ProSTEM Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.8.5 ProSTEM Recent Developments
  • 7.9 Cryoviva
    • 7.9.1 Cryoviva Profile
    • 7.9.2 Cryoviva Main Business
    • 7.9.3 Cryoviva Mesenchymal Stem Cells Products, Services and Solutions
    • 7.9.4 Cryoviva Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Cryoviva Recent Developments
  • 7.10 StemCells21
    • 7.10.1 StemCells21 Profile
    • 7.10.2 StemCells21 Main Business
    • 7.10.3 StemCells21 Mesenchymal Stem Cells Products, Services and Solutions
    • 7.10.4 StemCells21 Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.10.5 StemCells21 Recent Developments
  • 7.11 Lonza
    • 7.11.1 Lonza Profile
    • 7.11.2 Lonza Main Business
    • 7.11.3 Lonza Mesenchymal Stem Cells Products, Services and Solutions
    • 7.11.4 Lonza Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Lonza Recent Developments
  • 7.12 Thermo Fisher Scientific
    • 7.12.1 Thermo Fisher Scientific Profile
    • 7.12.2 Thermo Fisher Scientific Main Business
    • 7.12.3 Thermo Fisher Scientific Mesenchymal Stem Cells Products, Services and Solutions
    • 7.12.4 Thermo Fisher Scientific Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Thermo Fisher Scientific Recent Developments
  • 7.13 PromoCell
    • 7.13.1 PromoCell Profile
    • 7.13.2 PromoCell Main Business
    • 7.13.3 PromoCell Mesenchymal Stem Cells Products, Services and Solutions
    • 7.13.4 PromoCell Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.13.5 PromoCell Recent Developments
  • 7.14 Stemcell Technologies
    • 7.14.1 Stemcell Technologies Profile
    • 7.14.2 Stemcell Technologies Main Business
    • 7.14.3 Stemcell Technologies Mesenchymal Stem Cells Products, Services and Solutions
    • 7.14.4 Stemcell Technologies Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.14.5 Stemcell Technologies Recent Developments
  • 7.15 Bio-Techne
    • 7.15.1 Bio-Techne Profile
    • 7.15.2 Bio-Techne Main Business
    • 7.15.3 Bio-Techne Mesenchymal Stem Cells Products, Services and Solutions
    • 7.15.4 Bio-Techne Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.15.5 Bio-Techne Recent Developments
  • 7.16 ATCC
    • 7.16.1 ATCC Profile
    • 7.16.2 ATCC Main Business
    • 7.16.3 ATCC Mesenchymal Stem Cells Products, Services and Solutions
    • 7.16.4 ATCC Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.16.5 ATCC Recent Developments
  • 7.17 Merck
    • 7.17.1 Merck Profile
    • 7.17.2 Merck Main Business
    • 7.17.3 Merck Mesenchymal Stem Cells Products, Services and Solutions
    • 7.17.4 Merck Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.17.5 Merck Recent Developments

8 Industry Chain Analysis

  • 8.1 Mesenchymal Stem Cells Industrial Chain
  • 8.2 Mesenchymal Stem Cells Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Mesenchymal Stem Cells Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Mesenchymal Stem Cells Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Mesenchymal Stem Cells Market Trends
  • Table 2. Mesenchymal Stem Cells Market Drivers & Opportunity
  • Table 3. Mesenchymal Stem Cells Market Challenges
  • Table 4. Mesenchymal Stem Cells Market Restraints
  • Table 5. Global Mesenchymal Stem Cells Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Mesenchymal Stem Cells Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Mesenchymal Stem Cells Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Mesenchymal Stem Cells Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Mesenchymal Stem Cells
  • Table 10. Global Mesenchymal Stem Cells Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mesenchymal Stem Cells as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Mesenchymal Stem Cells Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Mesenchymal Stem Cells Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Mesenchymal Stem Cells Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Mesenchymal Stem Cells Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Mesenchymal Stem Cells Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Mesenchymal Stem Cells Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Mesenchymal Stem Cells Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Mesenchymal Stem Cells Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Mesenchymal Stem Cells Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Mesenchymal Stem Cells Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Mesenchymal Stem Cells Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Mesenchymal Stem Cells Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Mesenchymal Stem Cells Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Mesenchymal Stem Cells Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Mesenchymal Stem Cells Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Mesenchymal Stem Cells Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Mesenchymal Stem Cells Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Mesenchymal Stem Cells Sales Value, (2026-2031) & (US$ Million)
  • Table 31. CellResearch Basic Information List
  • Table 32. CellResearch Description and Business Overview
  • Table 33. CellResearch Mesenchymal Stem Cells Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Mesenchymal Stem Cells Business of CellResearch (2020-2025)
  • Table 35. CellResearch Recent Developments
  • Table 36. StemCord Basic Information List
  • Table 37. StemCord Description and Business Overview
  • Table 38. StemCord Mesenchymal Stem Cells Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Mesenchymal Stem Cells Business of StemCord (2020-2025)
  • Table 40. StemCord Recent Developments
  • Table 41. Cytopeutics Basic Information List
  • Table 42. Cytopeutics Description and Business Overview
  • Table 43. Cytopeutics Mesenchymal Stem Cells Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Cytopeutics (2020-2025)
  • Table 45. Cytopeutics Recent Developments
  • Table 46. CryoCord Basic Information List
  • Table 47. CryoCord Description and Business Overview
  • Table 48. CryoCord Mesenchymal Stem Cells Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Mesenchymal Stem Cells Business of CryoCord (2020-2025)
  • Table 50. CryoCord Recent Developments
  • Table 51. Cell Malaysia Basic Information List
  • Table 52. Cell Malaysia Description and Business Overview
  • Table 53. Cell Malaysia Mesenchymal Stem Cells Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Cell Malaysia (2020-2025)
  • Table 55. Cell Malaysia Recent Developments
  • Table 56. Bangkok Stem Cell Basic Information List
  • Table 57. Bangkok Stem Cell Description and Business Overview
  • Table 58. Bangkok Stem Cell Mesenchymal Stem Cells Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Bangkok Stem Cell (2020-2025)
  • Table 60. Bangkok Stem Cell Recent Developments
  • Table 61. Vinmec Stem Cell Institute Basic Information List
  • Table 62. Vinmec Stem Cell Institute Description and Business Overview
  • Table 63. Vinmec Stem Cell Institute Mesenchymal Stem Cells Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Vinmec Stem Cell Institute (2020-2025)
  • Table 65. Vinmec Stem Cell Institute Recent Developments
  • Table 66. ProSTEM Basic Information List
  • Table 67. ProSTEM Description and Business Overview
  • Table 68. ProSTEM Mesenchymal Stem Cells Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Mesenchymal Stem Cells Business of ProSTEM (2020-2025)
  • Table 70. ProSTEM Recent Developments
  • Table 71. Cryoviva Basic Information List
  • Table 72. Cryoviva Description and Business Overview
  • Table 73. Cryoviva Mesenchymal Stem Cells Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Cryoviva (2020-2025)
  • Table 75. Cryoviva Recent Developments
  • Table 76. StemCells21 Basic Information List
  • Table 77. StemCells21 Description and Business Overview
  • Table 78. StemCells21 Mesenchymal Stem Cells Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Mesenchymal Stem Cells Business of StemCells21 (2020-2025)
  • Table 80. StemCells21 Recent Developments
  • Table 81. Lonza Basic Information List
  • Table 82. Lonza Description and Business Overview
  • Table 83. Lonza Mesenchymal Stem Cells Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Lonza (2020-2025)
  • Table 85. Lonza Recent Developments
  • Table 86. Thermo Fisher Scientific Basic Information List
  • Table 87. Thermo Fisher Scientific Description and Business Overview
  • Table 88. Thermo Fisher Scientific Mesenchymal Stem Cells Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Thermo Fisher Scientific (2020-2025)
  • Table 90. Thermo Fisher Scientific Recent Developments
  • Table 91. PromoCell Basic Information List
  • Table 92. PromoCell Description and Business Overview
  • Table 93. PromoCell Mesenchymal Stem Cells Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Mesenchymal Stem Cells Business of PromoCell (2020-2025)
  • Table 95. PromoCell Recent Developments
  • Table 96. Stemcell Technologies Basic Information List
  • Table 97. Stemcell Technologies Description and Business Overview
  • Table 98. Stemcell Technologies Mesenchymal Stem Cells Products, Services and Solutions
  • Table 99. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Stemcell Technologies (2020-2025)
  • Table 100. Stemcell Technologies Recent Developments
  • Table 101. Bio-Techne Basic Information List
  • Table 102. Bio-Techne Description and Business Overview
  • Table 103. Bio-Techne Mesenchymal Stem Cells Products, Services and Solutions
  • Table 104. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Bio-Techne (2020-2025)
  • Table 105. Bio-Techne Recent Developments
  • Table 106. ATCC Basic Information List
  • Table 107. ATCC Description and Business Overview
  • Table 108. ATCC Mesenchymal Stem Cells Products, Services and Solutions
  • Table 109. Revenue (US$ Million) in Mesenchymal Stem Cells Business of ATCC (2020-2025)
  • Table 110. ATCC Recent Developments
  • Table 111. Merck Basic Information List
  • Table 112. Merck Description and Business Overview
  • Table 113. Merck Mesenchymal Stem Cells Products, Services and Solutions
  • Table 114. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Merck (2020-2025)
  • Table 115. Merck Recent Developments
  • Table 116. Key Raw Materials Lists
  • Table 117. Raw Materials Key Suppliers Lists
  • Table 118. Mesenchymal Stem Cells Downstream Customers
  • Table 119. Mesenchymal Stem Cells Distributors List
  • Table 120. Research Programs/Design for This Report
  • Table 121. Key Data Information from Secondary Sources
  • Table 122. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Mesenchymal Stem Cells Product Picture
  • Figure 2. Global Mesenchymal Stem Cells Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Mesenchymal Stem Cells Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Mesenchymal Stem Cells Report Years Considered
  • Figure 5. Global Mesenchymal Stem Cells Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Mesenchymal Stem Cells Revenue in 2024
  • Figure 7. Mesenchymal Stem Cells Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Umbilical Cord Derived MSC Picture
  • Figure 9. Bone Marrow Derived MSC Picture
  • Figure 10. Placenta Derived MSC Picture
  • Figure 11. Other Picture
  • Figure 12. Global Mesenchymal Stem Cells Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 13. Global Mesenchymal Stem Cells Sales Value Market Share by Type, 2024 & 2031
  • Figure 14. Product Picture of Research
  • Figure 15. Product Picture of Disease Treatment
  • Figure 16. Product Picture of Beauty and Anti-aging
  • Figure 17. Product Picture of Storage
  • Figure 18. Global Mesenchymal Stem Cells Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 19. Global Mesenchymal Stem Cells Sales Value Market Share by Application, 2024 & 2031
  • Figure 20. North America Mesenchymal Stem Cells Sales Value (2020-2031) & (US$ Million)
  • Figure 21. North America Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • Figure 22. Europe Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. Europe Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • Figure 24. Asia Pacific Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. Asia Pacific Mesenchymal Stem Cells Sales Value by Region (%), 2024 VS 2031
  • Figure 26. South America Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 27. South America Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Middle East & Africa Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. Middle East & Africa Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • Figure 30. Key Countries/Regions Mesenchymal Stem Cells Sales Value (%), (2020-2031)
  • Figure 31. United States Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. United States Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
  • Figure 33. United States Mesenchymal Stem Cells Sales Value by Application (%), 2024 VS 2031
  • Figure 34. Europe Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. Europe Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
  • Figure 36. Europe Mesenchymal Stem Cells Sales Value by Application (%), 2024 VS 2031
  • Figure 37. China Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 38. China Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
  • Figure 39. China Mesenchymal Stem Cells Sales Value by Application (%), 2024 VS 2031
  • Figure 40. Japan Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. Japan Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
  • Figure 42. Japan Mesenchymal Stem Cells Sales Value by Application (%), 2024 VS 2031
  • Figure 43. South Korea Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 44. South Korea Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
  • Figure 45. South Korea Mesenchymal Stem Cells Sales Value by Application (%), 2024 VS 2031
  • Figure 46. Southeast Asia Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 47. Southeast Asia Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
  • Figure 48. Southeast Asia Mesenchymal Stem Cells Sales Value by Application (%), 2024 VS 2031
  • Figure 49. India Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 50. India Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
  • Figure 51. India Mesenchymal Stem Cells Sales Value by Application (%), 2024 VS 2031
  • Figure 52. Mesenchymal Stem Cells Industrial Chain
  • Figure 53. Mesenchymal Stem Cells Manufacturing Cost Structure
  • Figure 54. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 55. Bottom-up and Top-down Approaches for This Report
  • Figure 56. Data Triangulation
  • Figure 57. Key Executives Interviewed
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!